Navigation Links
S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders
Date:12/10/2007

Data Presented on Three S*BIO Compounds at The American Society of

Hematology 2007

SINGAPORE, Dec. 10 /PRNewswire/ -- S*BIO Pte Ltd today announced the data presentation on its most advanced compounds at The American Society of Hematology 49th Annual Meeting and Exposition in Atlanta, Georgia. An oral presentation made on its novel and selective JAK2 inhibitor SB1518 highlighted the therapeutic potential of SB1518 for the treatment of myeloproliferative disorders.

In addition, a poster was presented on S*BIO's orally-active "best-in- class" HDAC inhibitor SB939 detailing its therapeutic potential for the treatment of hematological malignancies while a poster on S*BIO's novel kinase inhibitor SB1317 showed data for the potential treatment of acute leukemias.

"We are pleased to announce data for the first time on our JAK2 inhibitor, SB1518, and its potential treatment of myeloproliferative disorders, an area of great unmet medical need," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "We are currently conducting Phase I clinical trials for SB939 in Canada and Singapore, and expect the initiation of Phase I trials in various centers in the U.S. We are also delighted to report data on our Flt3-CDK inhibitor, SB1317. The data presented clearly demonstrate the strength and diversity of S*BIO's pipeline and validate our target-driven approach in developing 'best-in-class' and 'first-in-class' drugs."

Oral Presentation (Session: Molecular Pharmacology -- Novel Therapies I)

SB1518: A potent and orally-active JAK2 Inhibitor for the treatment of myeloproliferative disorders

SB1518, a potent ATP-competitive inhibitor of both JAK2 kinase, and its JAK2V617F mutant, demonstrated therapeutic potential for the treatment of myeloproliferative disorders caused by aberrant JAK2 signaling. JAK2 is the most common mutated gene in bcr-abl-negative chronic myeloproliferative disorders (MPDs).

Poster No. 7
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
3. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
4. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
5. Silencing small but mighty cancer inhibitors
6. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
7. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
8. Highmarks Hospital Pay-for-Performance Program Demonstrates Impressive Results
9. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
10. LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon
11. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Healthpointe is pleased to provide ... students via Clinical Rotations. Physical Therapy ... Healthpointe providers and specialists throughout their daily clinical ... experience and learn professional preparation. , ... into several patient care techniques and expand their ...
(Date:8/29/2014)... 2014 Pursuing its deepest desires to ... unveil a stunning new design that promises to redefine ... highly notable surrogacy platform has witnessed a 42 percent ... visitors a month, the FindSurrogateMother.com community is formed by ... common goal — the precious gift of life. , ...
(Date:8/29/2014)... based on administering antidepressants for acute and chronic ... are needed to determine whether these drugs should ... basis., Dr. Ian Gilron, a professor and director ... Anesthesiology, and his team of seven researchers reviewed ... antidepressants for pain relief post-surgery would work more ...
(Date:8/29/2014)... Grove Village, IL (PRWEB) August 29, 2014 ... innovator in hearing wellness solutions, is on its way ... 15-17 at the San Diego Convention Center to exhibit ... those who work in high-noise industrial environments. Etymotic’s safety ... the hottest wearable technology devices at the show. ...
(Date:8/29/2014)... Elk Grove Village, IL (PRWEB) August 29, 2014 ... welcomed Kathleen Baty, “The Safety Chick” who profiled ... including ETY•Kids® Safe-Listening Earphones from Etymotic Research. This ... school supply list, and Etymotic, an innovator of ... for young ears. Their ETY•Kids Safe-Listening Earphones, offered ...
Breaking Medicine News(10 mins):Health News:Healthpointe is Now Offering Clinical Rotations for Chapman University Physical Therapy Students 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3Health News:Antidepressants show potential for postoperative pain 2Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2Health News:The Today Show Features ETY•Kids® Safe-Listening Earphones by Etymotic 2
... Today at 9:00am ET , , Covers Europe, ... , , Includes Licensing Option and ... Calif. and STAINES, England, June 22 NeurogesX, Inc. (Nasdaq: ... Tokyo based Astellas Pharma Inc. announced today that the companies have entered ...
... ... company , ... Colo. (PRWEB) June 22, 2009 -- Silver Creek Systems®, the pioneer and ... that their DataLens™ System was selected by McKesson Medical-Surgical to automate the processes that ...
... "Anesthesia & Me"(C) Checklist to Help Patients Organize ... , LifelinetoModernMedicine.com Provides Patients with Physician-Certified Tools ... 22 Every year, 46 million Americans face ... help educate and inform prospective patients and the ...
... self-help technique called guided imagery has been steadily gaining ... insurance companies, as new research demonstrates its efficacy for ... June 22 A new self-help audio recording designed ... or other viral and bacterial illnesses was released this ...
... June 22 /PRNewswire-Asia/ -- The Healthcare & Science,business ... a Memorandum of,Understanding (MOU) with the Science & ... organization under the National,Applied Research Laboratories in Taiwan, ... Taiwan,s Science & Technology (S&T) development. , ...
... , ... resource in the compounding pharmacy industry had just been released by Esco. The videos ... ... announces the release of its new series of safety and education videos for the ...
Cached Medicine News:Health News:NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) 2Health News:NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) 3Health News:NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) 4Health News:NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) 5Health News:NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM) 6Health News:McKesson Medical-Surgical Selects DataLens System to Automate Product Data Mastering 2Health News:American Society of Anesthesiologists Launches Web Site Focused on Educating and Empowering the Public about Anesthesiology 2Health News:American Society of Anesthesiologists Launches Web Site Focused on Educating and Empowering the Public about Anesthesiology 3Health News:Cancer Patients Use New Guided Imagery CD to Help Boost Healthy Immune Functioning 2Health News:Cancer Patients Use New Guided Imagery CD to Help Boost Healthy Immune Functioning 3Health News:Taiwan's Science & Technology Policy Research and Information Center (STPI) and Thomson Reuters Sign MOU of Collaboration to Support Science & Technology Development 2Health News:Taiwan's Science & Technology Policy Research and Information Center (STPI) and Thomson Reuters Sign MOU of Collaboration to Support Science & Technology Development 3Health News:New Compounding Pharmacy Videos Provide Product Information, Teach Safety 2Health News:New Compounding Pharmacy Videos Provide Product Information, Teach Safety 3
(Date:8/29/2014)...   Mast Therapeutics, Inc. (NYSE MKT: ... Santosh Vetticaden, Chief Medical Officer and Senior Vice ... reasons, in mid-September.  Edwin L. Parsley , ... which Mast acquired earlier this year, will assume ... Chief Medical Officer.  Dr. Parsley previously was with ...
(Date:8/29/2014)... Research and Markets has announced ... Market & Pipeline Insight 2014" report to their ... prevent and eradicate the prevalence of cancer have achieved ... to low specificity, safety and large number of side ... better solution. It has been discovered that peptides can ...
(Date:8/29/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) ... District of New Jersey has ... Sandoz, Inc. regarding United Therapeutics, Remodulin ® product.  In ... U.S. Patent No. 6,765,117 is both valid and enforceable ... generic product until the expiration of that patent in ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
... off daily GERD medication at 1 year ... after transoral incisionless fundoplication surgery, REDMOND, Wash., ... natural orifice surgery products and procedures, announces,outstanding results ... patients,in the phase 2 multi-center study of the ...
... Dong-A PharmTech Co., Ltd.,announced today that its ... patient, phase 2 proof of concept clinical study ... phosphodiesterase type 5 inhibitor, for,portal hypertension, an unmet ... investigate the safety and efficacy of udenafil in ...
Cached Medicine Technology:EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study 2EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study 3EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study 4Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil 2Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: